Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Zoetis Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Zoetis kazanç ve gelirin sırasıyla yıllık 10.2% ve 6.1% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 11% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 45.4% olacağı tahmin edilmektedir.

Anahtar bilgiler

10.2%

Kazanç büyüme oranı

11.0%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	23.8%
Gelir büyüme oranı	6.1%
Gelecekteki özkaynak getirisi	45.4%
Analist kapsamı	Good
Son güncelleme	03 Oct 2024

Gelecekteki son büyüme güncellemeleri

The Zoetis Inc. (NYSE:ZTS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 04

Recent updates

The Zoetis Inc. (NYSE:ZTS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 04

Zoetis: Long-Term Buy Despite Safety Concerns

May 03

Despite Lawsuit Risks: Why Zoetis Remains A Compelling Investment

Apr 15

Zoetis Inc.'s (NYSE:ZTS) Shareholders Might Be Looking For Exit

Apr 12

Zoetis: My Favorite Healthcare Stock Right Now

Mar 21

Estimating The Fair Value Of Zoetis Inc. (NYSE:ZTS)

Mar 03

Zoetis: Buy This High-Quality Dividend Growth Beast On Weakness

Feb 27

Animal Kingdom's Ally: Zoetis And Its Path To 10%+ Returns

Jan 10

Some Confidence Is Lacking In Zoetis Inc.'s (NYSE:ZTS) P/E

Jan 01

Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's

Dec 14

Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?

Dec 06

Here's Why We Think Zoetis (NYSE:ZTS) Might Deserve Your Attention Today

Nov 18

Zoetis: High-Quality Compounder With A Reasonable Price After Earnings

Nov 09

Zoetis: Significant CapEx Investments For Long-Term Growth, But A Hold Now

Oct 26

Zoetis Is An Impressive Healthcare Compounder

Sep 26

Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

Sep 25

Here's Why Zoetis (NYSE:ZTS) Can Manage Its Debt Responsibly

Sep 04

Zoetis: Pawses Pain, Librela OA Treatment Targets Furry Friends In The U.S.

Aug 22

Should You Be Adding Zoetis (NYSE:ZTS) To Your Watchlist Today?

Aug 12

Zoetis: My Dog Approves Of This Dividend Compounder

Jul 19

Zoetis: A Purrfect Addition To Your Portfolio

Jun 22

Does This Valuation Of Zoetis Inc. (NYSE:ZTS) Imply Investors Are Overpaying?

Jun 10

These 4 Measures Indicate That Zoetis (NYSE:ZTS) Is Using Debt Reasonably Well

Apr 16

Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

Mar 10

Zoetis rises on 2023 revenue forecast above estimates, Q4 profit in-line with consensus

Feb 14

Zoetis Is An Awesome Dividend Growth Stock

Jan 17

It's A Great Time To Buy Zoetis Shares

Jan 10

Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's

Jan 03

Is Zoetis (NYSE:ZTS) Using Too Much Debt?

Dec 29

Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's

Dec 14

Kazanç ve Gelir Büyüme Tahminleri

NYSE:ZTS - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	10,449	3,028	2,987	3,439	13
12/31/2025	9,806	2,735	2,721	3,268	15
12/31/2024	9,185	2,468	2,164	2,738	15
6/30/2024	8,915	2,344	2,103	2,718	N/A
3/31/2024	8,734	2,391	1,750	2,399	N/A
12/31/2023	8,544	2,344	1,621	2,353	N/A
9/30/2023	8,371	2,280	1,492	2,197	N/A
6/30/2023	8,222	2,213	1,285	1,999	N/A
3/31/2023	8,094	2,071	1,458	2,152	N/A
12/31/2022	8,080	2,114	1,326	1,912	N/A
9/30/2022	8,007	2,067	1,267	1,850	N/A
6/30/2022	7,995	2,090	1,429	1,977	N/A
3/31/2022	7,891	2,073	1,607	2,122	N/A
12/31/2021	7,776	2,037	1,736	2,213	N/A
9/30/2021	7,616	1,982	1,791	2,252	N/A
6/30/2021	7,412	1,909	1,702	2,161	N/A
3/31/2021	7,012	1,774	1,682	2,118	N/A
12/31/2020	6,675	1,638	1,673	2,126	N/A
9/30/2020	6,542	1,663	1,523	1,990	N/A
6/30/2020	6,340	1,617	1,456	1,934	N/A
3/31/2020	6,339	1,611	1,323	1,814	N/A
12/31/2019	6,260	1,500	1,335	1,795	N/A
9/30/2019	6,150	1,461	1,365	1,797	N/A
6/30/2019	6,046	1,375	1,463	1,841	N/A
3/31/2019	5,914	1,388	1,442	1,790	N/A
12/31/2018	5,825	1,428	1,452	1,790	N/A
9/30/2018	5,721	1,164	1,531	1,814	N/A
6/30/2018	5,588	1,115	1,446	1,703	N/A
3/31/2018	5,442	978	N/A	1,616	N/A
12/31/2017	5,307	864	N/A	1,346	N/A
10/1/2017	5,124	937	N/A	1,024	N/A
7/2/2017	5,018	878	N/A	824	N/A
4/2/2017	4,957	855	N/A	781	N/A
12/31/2016	4,888	821	N/A	713	N/A
10/2/2016	4,885	689	N/A	705	N/A
7/3/2016	4,858	639	N/A	670	N/A
4/3/2016	4,825	378	N/A	655	N/A
12/31/2015	4,765	339	N/A	664	N/A
9/27/2015	4,811	443	N/A	773	N/A
6/28/2015	4,807	420	N/A	672	N/A
3/29/2015	4,790	593	N/A	709	N/A
12/31/2014	4,785	583	N/A	626	N/A
9/28/2014	4,719	562	N/A	537	N/A
6/29/2014	4,612	527	N/A	548	N/A
3/30/2014	4,568	519	N/A	377	N/A
12/31/2013	4,561	504	N/A	681	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: ZTS 'nin tahmini kazanç büyümesi (yıllık 10.2% ) tasarruf oranının ( 2.5% ) üzerindedir.

Kazançlar ve Piyasa: ZTS şirketinin kazançlarının (yıllık 10.2% ) US pazarından (yıllık 15.2% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: ZTS şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: ZTS şirketinin gelirinin (yıllık 6.1% ) US pazarından (yıllık 8.7% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: ZTS şirketinin gelirinin (yıllık 6.1% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: ZTS 'nin Özsermaye Getirisi'nin 3 yıl içinde çok yüksek olması tahmin ediliyor ( 45.4 %).

Zoetis Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Zoetis Inc. Raises Earnings Guidance for the Year 2024

The Zoetis Inc. (NYSE:ZTS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Zoetis Inc. Revises Earnings Guidance for the Year 2024

Zoetis Inc. Provides Earnings Guidance for the Full Year 2023

Zoetis Inc. Maintains Earnings Guidance for the Full Year 2023

Zoetis Inc. Provides Earning Guidance for Full Year 2023

Recent updates

Zoetis: Investing In Pet Health And Portfolio Wealth

Are Investors Undervaluing Zoetis Inc. (NYSE:ZTS) By 23%?

Zoetis to Introduce First Cartridge-Based AI-Powered Hematology Analyzer

There's Reason For Concern Over Zoetis Inc.'s (NYSE:ZTS) Price

Now 22% undervalued

Zoetis: Librela Sales Should Peak 200-300% Above Management's $1B Target

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Zoetis Q2 Earnings: Harvesting From DTC (Rating Upgrade)

Zoetis Inc. Raises Earnings Guidance for the Year 2024

Zoetis Inc. (NYSE:ZTS) announces an Equity Buyback for $6,000 million worth of its shares.

Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?

Upcoming dividend of US$0.43 per share

Executive VP & CFO exercised options and sold US$2.4m worth of stock

Zoetis: A High-Quality Business And Fast Dividend Growth At A Reasonable Price

Zoetis: Don't Fret Excessively Over The Animal Healthcare Leader

A Look At The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

First quarter dividend of US$0.43 announced

Zoetis Inc. Announces Retirement of Linda Rhodes as Board of Directors

Zoetis (NYSE:ZTS) Ticks All The Boxes When It Comes To Earnings Growth

Zoetis Inc. Declares Dividend for the Third Quarter of 2024, Payable on September 4, 2024

Zoetis: Why The Focus On Companion Animal Segment Will Pay Off

Employee Advisor notifies of intention to sell stock

The Zoetis Inc. (NYSE:ZTS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Zoetis: Long-Term Buy Despite Safety Concerns

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Zoetis Inc. Revises Earnings Guidance for the Year 2024

Phibro Animal Health Corporation (NasdaqGM:PAHC) entered into a definitive agreement to acquire Medicated feed additive product portfolio, certain water soluble products and related assets of Zoetis Inc. (NYSE:ZTS) for approximately $350 million.

Zoetis Inc. Announces Executive Changes

Despite Lawsuit Risks: Why Zoetis Remains A Compelling Investment

Now 22% undervalued after recent price drop

Zoetis Inc.'s (NYSE:ZTS) Shareholders Might Be Looking For Exit

Zoetis Inc., Annual General Meeting, May 22, 2024

Upcoming dividend of US$0.43 per share

Zoetis Inc. Appoints Gavin D.K. Hattersley to Its Board of Directors

Zoetis: My Favorite Healthcare Stock Right Now

Estimating The Fair Value Of Zoetis Inc. (NYSE:ZTS)

Zoetis: Buy This High-Quality Dividend Growth Beast On Weakness

CEO & Director notifies of intention to sell stock

CEO & Director exercised options and sold US$3.6m worth of stock

Full year 2023 earnings: EPS misses analyst expectations

Dividend of US$0.43 announced

Zoetis Inc. Declares Second Quarter 2024 Dividend, Payable on June 4, 2024

Upcoming dividend of US$0.43 per share at 0.9% yield

Animal Kingdom's Ally: Zoetis And Its Path To 10%+ Returns

Some Confidence Is Lacking In Zoetis Inc.'s (NYSE:ZTS) P/E

Insufficient new directors

Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's

Zoetis Inc. Declares Dividend for the First Quarter of 2024, Payable on March 1, 2024

Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?

CEO & Director exercised options and sold US$1.7m worth of stock

Here's Why We Think Zoetis (NYSE:ZTS) Might Deserve Your Attention Today

Zoetis: High-Quality Compounder With A Reasonable Price After Earnings

Zoetis Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Zoetis: Significant CapEx Investments For Long-Term Growth, But A Hold Now

Upcoming dividend of US$0.38 per share at 0.9% yield

Zoetis Inc. Declares Dividend for the Fourth Quarter of 2023, Payable on December 1, 2023

Zoetis Is An Impressive Healthcare Compounder

Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

Executive VP notifies of intention to sell stock

Zoetis Inc. (NYSE:ZTS) acquired adivo GmbH from founders, High-Tech Gründerfonds, the Swiss Occident Group AG and MorphoSys AG (XTRA:MOR).

Zoetis Inc. (NYSE:ZTS) acquired adivo GmbH.

Here's Why Zoetis (NYSE:ZTS) Can Manage Its Debt Responsibly

CEO & Director exercised options and sold US$1.7m worth of stock

Zoetis: Pawses Pain, Librela OA Treatment Targets Furry Friends In The U.S.

Should You Be Adding Zoetis (NYSE:ZTS) To Your Watchlist Today?

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Zoetis: My Dog Approves Of This Dividend Compounder

Upcoming dividend of US$0.38 per share at 0.9% yield